for the Period Ended 31 December 2023
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
As at
Notes | 2023 | 2022 | |
---|---|---|---|
|
£ |
£ |
|
Current assets | |||
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Creditors: amounts falling due after more than one year: | 3 |
(
|
(
|
Total net assets (liabilities): |
( |
( |
|
Members' funds | |||
Profit and loss account: |
( |
( |
|
Total members' funds: |
( |
( |
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2023
Basis of measurement and preparation
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 December 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Other creditors |
|
|
Total |
|
|
1. Ongoing Achievements and Workstreams a. Of particular merit was the commission of a major 5 country survey which established much useful information about the benefits of ALL member states allowing the obtaining of prescription medicines online. A comprehensive report was published and can be found online. and a new website forming a new alliance can be found here (www.onhomealliance.eu). The OnHOME Alliance was created to form a united front so that the 19 Member States who currently do not allow prescription medicines to be obtained online can do so. This will hopefully be achieved by the amendment to article 172 of the General Pharmaceutical legislation. b. In collaboration with the EAEP, a joint survey with Member States was carried responsible for the governance of the Common Logo under the Falsified Medicines Directive. The published report can be found online and will be used to encourage Member States to honour article 85D which legally obliges the public to be informed about the meaning of a falsified medicine as well as the Common Logo. c. ASOP EU has worked closely with the NABP to further the subscriptions of onlin pharmacies to adopt the Top level Domain name DotPharmacy. if the consumer knows of this website, then they can be assured of legitimate and authentic medicines. These ativities were continued during 2023. in particular, closer liaison activity took place with the NABP attempting to introduce DotPharmacy gLTD into the UK and also Member States. d. A new closer collaboration with the European association of E-pharmacies has resulted in the DotPharmacy principle being of more interest in Europem and the vision is to introduce this concept using the translated term such as DotPharmacie for France, Dot Apoteke for Germany etc. e. The Digital Services Act (DSA) has replaced the E-Commerce Act, and is a truely significant event and ASOP EU are advocating strongly for more liability to be placed on the Internet Intermediaries. Close affiliation with ASOP Global and contributing to the Global initiatives, which include a parrallel pathway with communications to the VP at the White House and advocacy in the US Congress, and close liaison with Homeland Security and the FDA. In Europe, ASOP EU became a strong member of the Know Your Business Customer (KYBC Community) and was one of 86 organisations to be part of this community advocating for a broadened scope of the DSA to include all intermediaries not just online marketplaces. ASOP EUU wrote letters to the Commission, the Council and the Parliament, as well as the President advocation for the KYBC principles. During 2022, the above advocacy has continued and ASOP EU is now closely monitoring the implementation of the DSA. Recently, a meeting was convened with key players in the pharmaceutical industry the EUIPO/Observatory to raise awareness about the practical effect of the DSA introduction and how it will aid better governance of the internet. ASOP EU in collaboration with the EUIPO Observatory held an educational meeting bringing together major big pharma to ensure that illegal or suspicious activity is reported to the Commission DG Connect who has the responsibility of policing the new ACT. ASOP EU continues to highlight the need to stakeholders that only reporting 'bad' activity can the DSA become most useful in combating falsified medicines and saving the public from harm. f. Advocating for an enhanced NIS2 legislation by working closely with the KYBC community. Further UK legislation is in the offing, and the ASOP EU contributed to a recent submission. g. Being part of the EUIPO Observatory as a Civil Society Member and a speaker championing the rights of patient safety in the various working groups. ASOP EU was part of an expert WG on Domain Names, and a comprehensive report was issued on this subject to underline best practice in this area. This support to the observatory continued in 2023. ASOP EU has now been part of two significant expert working groups (EWG) notably the 'Domain Names' EWG and the 'Search Engine' EWG. ASOP EU presented in plenary for a new expert group on falsified medicines. h. As per point 1 - participating in endorsing the NABP .pharmacy initiative and being part of the .Pharmacy Registrant/Supporter Advisory Committee, and championing the .pharmacy initiative as a more robust solution than the Common Logo which has already been cut and pasted by criminals. 2. ASOP EU became official observers of the Committee of Parties (CotP) Member of the ratified Medicrime Convention. ASOP EU are in the process of recommending the DOT pharmacy initiative to the CotP, as well as running longitudinal market research by each ratified country. ASOP EU attended the 4Q meeting in Strasbourg and presented in Plenary the ideas to help develop the reach of the Medicrime Convention. These can be found in the Summer newsletter . This initiative is ongoing and due to a hiatus in the MC proceedings, it was delayed. 3. Production of a July 2023/24 newsletter. 4. Many speaking engagements including invitations to speak at various conferences took place - a summary of which can be found on page 14 of the newsletter.
Consultation is ongoing throughout the year with Members and Observers. The relationship with law enforcement with the MHRA has been particularly strong, as is the relationship with its sister organisation ASOP Global. Currently ASOP EU is in liaison with the MHRA to champion a Google demote initiative, which has the potential to drive illegal websites down the search engine tree. ASOP EU also facilitated EURid and the National Association of Boards of Pharmacy (NABP) acting synergistically to check suspicious websites. This activity is now in abeyance due to the platform DotEU being essentially cleaned of bad actors. Close liaison with the Secretariat of the Medicrime Convention Committee of the Parties took place and attendance at the virtual meetings. 2023, like 2022, was characterised by an enhanced meeting schedule held virtually. Advocacy letters on the Digital Services Act involved other organisations as co-signatories and the letter can be found online. Discussions with the European Association for e-pharmacies were ongoing which resulted in them rejoining as members and an agreement to work together more closely. A new director was appointed who is the head of the Brussels advocacy office of the EAEP.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
12 August 2024
And signed on behalf of the board by:
Name: M P Isles
Status: Director